Completed PHASE2 INTERVENTIONAL NCT00202553

S90652 in Paediatric Hypertension

Acceptability, Safety, Pharmacokinetics and Effects on Blood Pressure of a Daily Dose of 0.025 to 0.135 Milligram Per Kilogram of S90652, a Paediatric Formulation of Perindopril, in 2-16 Years Old Hypertensive Children - 3 Month Study

Sponsor: Institut de Recherches Internationales Servier

Conditions Hypertension

Interventions Perindopril

Updated 5 times since 2017 Last updated: Apr 10, 2018 Started: Jul 31, 2003 Completion: Dec 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00202553, this PHASE2 trial focuses on Hypertension and remains completed. Sponsored by Institut de Recherches Internationales Servier, it has been updated 5 times since 2003, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jul 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Institut de Recherches Internationales Servier

Data source: Servier

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Paris, France